repotrectinib (Augtyro)
Jump to navigation
Jump to search
Indications
- treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer
- all NTRK gene fusion+ solid tumors[1]
Dosage
Capsules: 40 mg
Adverse effects
- > 20%
- dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, ataxia, fatigue, cognitive disorders, muscle weakness
Drug interactions
- strong & moderate CYP3A inhibitors: avoid concurrent use
- P-glucoprotein inhibitors: avoid concurrent use
- strong & moderate CYP3A inducers: avoid concurrent use
- hormonal contraceptives: avoid concurrent use
Mechanism of action
- inhibits ROS1 & tropomyosin receptor tyrosine kinases TRKA, TRKB, & TRKC
More general terms
References
- ↑ 1.0 1.1 Alexander Otto M FDA Expands Repotrectinib Label to All NTRK Gene Fusion+ Solid Tumors. Medscape. June 13, 2024 https://www.medscape.com/viewarticle/fda-expands-repotrectinib-label-all-ntrk-gene-fusion-solid-2024a1000b3q
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION Augtyro <TM> (repotrectinib) capsules, for oral use https://packageinserts.bms.com/pi/pi_augtyro.pdf